Pain Management in Lung Cancer

Nurwidya, Fariz; Syahruddin, Elisna; Yunus, Faisal

doi:10.5603/arm.2016.0043

Cited by 4 publications

(3 citation statements)

References 76 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…All these findings suggest that clinicians resort to other drugs to improve opioid analgesia, rather than increasing the doses of opioids, as pain would be less responsive to opioid drugs [9]. The use of adjuvant drugs is suggested by a recent study in which duloxetine and pregabalin were found to be effective in lung cancer patients with neuropathic pain [16].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Breakthrough Pain in Patients with Lung Cancer. A Secondary Analysis of IOPS MS Study

Mercadante

Masedu

Valenti

et al. 2020

JCM

View full text Add to dashboard Cite

Aim: To characterize breakthrough cancer pain (BTcP) in patients with lung cancer. Methods: This was a secondary analysis of multicenter study of patients with BTcP. Background pain intensity and opioid dose were recorded. The number of BTcP episodes, their intensity, predictability, onset, duration and interference with daily activities were collected. Opioids used for BTcP, the mean time to meaningful pain relief after taking medication, satisfaction and adverse effects were assessed. Results: 1087 patients with lung cancer were examined. In comparison with other tumors, patients with lung cancer showed: higher background pain intensity (p = 0.006), lower opioid doses (p = 0.005), higher intensity of BTcP (p = 0.005), movement (79.5%) and cough (8.2%), as principal triggers for predictable BTcP (p < 0.009), larger BTcP interference with daily activity (p = 0.0001), higher use of adjuvants (p = 0.0001). No relevant differences in the other parameters examined were found. Conclusion: Patients with lung cancer have their own peculiarities, including higher basal and BTcP pain intensity and the use of more adjuvant drugs for background pain. The most frequent triggers for predictable BTcP are movement and cough. Future studies should be performed to analyze the prevalence of BTcP in patients with different lung cancers as well as the optimal management strategy for background pain and BTcP.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Cancer pain management is difficult and may sub-optimal in many circumstances. Different factors, including poor pain assessment, inadequate knowledge and sub-optimal prescription of analgesics and poor capabilities to manage opioid adverse-effects may result in an undertreatment [9].…”

Section: Introductionmentioning

confidence: 99%

Breakthrough Pain in Patients with Lung Cancer. A Secondary Analysis of IOPS MS Study

Mercadante

Masedu

Valenti

et al. 2020

JCM

View full text Add to dashboard Cite

show abstract

“…Adjuvants of pain continued and were adjusted as needed. Those included, pregabalin, gabapentin, duloxetine, nortriptyline, amitriptyline, NSAIDS, and muscle relaxants (23,24). As with all patients in the center, patients were encouraged to participate in mindbody medicine and acupuncture to assist with pain and coping mechanisms (25).…”

Section: Resultsmentioning

confidence: 99%

Low Volume Neurolytic Retrocrural Celiac Plexus Block for Visceral Cancer Pain: Retrospective Review of 507 Patients with Severe Malignancy Related Pain Due to Primary Abdominal Cancer or Metastatic Disease

Rahman

Macrinici

et al. 2018

Pain Phys

View full text Add to dashboard Cite

Background: Abdominal pain from primary cancer or metastatic disease is a significant cause of pain for patients undergoing treatment for the disease. Patient’s pain may be resistant to conventional analgesics. The need for timely pain relief in order to facilitate further care in the cancer treatment plan should be a priority. Objectives: The aim of this retrospective observational review was to assess the relief given with a low volume neurolytic retrocrural celiac plexus nerve block, the duration of the procedure, the duration of relief, the reduction in daily opioid consumption, and the improvement of quality of life in a patient suffering from incapacitating abdominal pain due to primary abdominal malignancy or abdominal metastatic disease. Patients were given a neurolytic celiac plexus block without previous diagnostic block due to multiple comorbidities. Study Design: This is a retrospective, observational study. Methods: Five hundred and seven patients were studied and data at 5 months for 455 patients were retained at the end of the review. They were evaluated in the pain center prior to and after the neurolytic retrocrural celiac plexus nerve block under fluoroscopic guidance. They were assessed on duration of procedure, pain scores (numeric rating scale 0-10), daily opioid consumption, quality of life improvement (simple yes or no question at 3 months) and routine follow-up during treatment for the cancer for 6 months or end of life. All data was gathered by extensive chart review and placed on a spreadsheet for analysis. Results: Follow-up was completed 6 months after the procedure. Pain scores, daily opioid consumption, and quality of life showed improvement for the duration of the study. There was some return in pain during the fourth to sixth month due to disease progression and the anticipated duration of the neurolytic agent. Some short duration known side effects did occur. An initial vascular contrast uptake of 6.7% was noted during the procedure while utilizing digital subtraction angiography with fluoroscopy. Limitations: A larger sample size would be ideal, as well as, a prospective trial with a control group, but this is unrealistic in our patient population. A proven quality of life questionnaire would be beneficial. Comparing alcohol, phenol and radiofrequency thermocoagulation would be interesting to equate duration, effect, and side effects. Conclusion: Low volume neurolytic retrocrural celiac plexus nerve block with phenol is a safe procedure providing up to 6 months of pain relief and is an effective, well-established, minimally time-consuming procedure for abdominal pain due to primary malignancy or metastatic spread. Key words: Celiac plexus, neurolytic, abdominal cancer pain, pain, retrocrural, cancer pain

show abstract

White matter microstructure damage measured by automated fiber quantification correlates with pain symptoms in lung cancer patients

Ran,

Liu,

Lan

et al. 2024

Brain Imaging and Behavior

View full text Add to dashboard Cite

Pain Management in Lung Cancer

Cited by 4 publications

References 76 publications

Breakthrough Pain in Patients with Lung Cancer. A Secondary Analysis of IOPS MS Study

Breakthrough Pain in Patients with Lung Cancer. A Secondary Analysis of IOPS MS Study

Low Volume Neurolytic Retrocrural Celiac Plexus Block for Visceral Cancer Pain: Retrospective Review of 507 Patients with Severe Malignancy Related Pain Due to Primary Abdominal Cancer or Metastatic Disease

White matter microstructure damage measured by automated fiber quantification correlates with pain symptoms in lung cancer patients

Contact Info

Product

Resources

About